Glutamyl transpeptidase is abundant in the kidneys, liver and pancreas, but the main source of glutamyl transpeptidase in human blood is the biliary system in the liver. In clinical practice, this indicator is mostly used to assess liver function, with normal values ranging from 3 to 50 U/L. If the liver function results suggest a glutamyl transpeptidase of 120 U/L, the patient is mostly considered to have abnormal liver function, which means that the patient may have liver insufficiency or hepatocyte necrosis. Whether this condition is serious or not needs to be decided according to the specific condition and should not be judged based on a single index. If the patient has viral hepatitis, autoimmune hepatitis, and has long-term cholestasis that causes elevated glutamyl transpeptidase, it suggests a more serious condition and needs to be actively managed to avoid more serious diseases caused by continued liver damage. If the examination suggests viral hepatitis, and the DNA of hepatitis B or RNA of hepatitis C indicates that the virus has replicated, active antiviral treatment should be carried out along with liver protection therapy. The hepatoprotective treatment can choose oral hepatoprotective tablets, reduced glutathione and Kessler, etc., and can also consider intravenous infusion of reduced glutathione or hepatocyte growth promoter and other related drugs. In conclusion, the elevation of this index should be analyzed together with transaminases, bilirubin, alkaline phosphatase, ultrasound and other related tests to clarify the cause.